

Carasent ASA acquires Data-AI and enters the German market – invitation to webcast 29 October 11:00 CET

Carasent ASA (“Carasent”) has today acquired the German company Data-AI GmbH (“Data-AI”), a provider of electronic health record (“EHR”) solutions for private healthcare clinics in Germany with more than 1,000 customers and a long successful track record in the German market. Carasent has updated its financial targets for 2025 to reflect the acquisition.

Acquisition of Data-AI

Founded in Germany in 1988, Data-AI provides the EHR solutions Data-AI and Data-Cur. Data-AI has a local organisation of 30 employees with deep knowledge of local requirements, and a strong market position with more than 1,000 customers across most parts of Germany. Data-AI works with the same type of customers as Webdoc, small to medium sized private clinics.

Data-AI’s financial metrics are typical of the industry, including sticky revenue streams and low customer churn, which provide a stable foundation for long-term growth. Data-AI’s revenues and EBITDA in 2023 were approximately EUR 4.0 million and EUR 0.5 million. The transaction values Data-AI at an enterprise value of EUR 8 million, with potential additional earnout payments of up to EUR 4 million pending future growth.

Carasent CEO Daniel Öhman comments:

“After a comprehensive and intense screening process we are delighted to have finally entered the German market with full force. We have been following Data-AI for almost one year and believe we have found a perfect match, combining a highly competent team with a very strong market standing and attractive customer base. Having this foundation will be crucial as we roll out Webdoc X in the German market.”

Updated financial targets

Following the acquisition of Data-AI, Carasent is updating the financial targets for 2025 to account for the additional revenue and EBITDA contribution expected from the acquisition. The organic financial targets excluding Data-AI remain unchanged.

Financial targets 2025 (previous targets):

- Revenues around NOK 360 million (320 million)
- EBITDA around NOK 85-90 million (80 million)
- EBITDA – capex around NOK 45-50 million (40 million)
- EBITDA – capex of NOK 60 million excluding Germany

Carasent is executing its strategy to reach targets with the current company structure. Additional potential acquisitions and divestments are not included. The financial targets are intended for a long-term perspective, and there will be variations between quarters. The new targets for 2025 replace the financial targets announced on 24 April 2024.

Carasent will host a webcast to present the acquisition on the 29th of October at 11:00 CET.

Please use the following link to access the presentation:

[Carasent press conferece 2024](#)

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

[Call Access](#)

For further details please contact:

Daniel Öhman, CEO Tel: +46 70-855 37 07, or
Svein Martin Bjørnstad, CFO Tel: +47 979 69 493

This information is information that Carasent is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-28 14:16 CET.